Verastem Oncology To Report Progress Across VS-7375 Oral KRAS G12D (ON/OFF) TARGET-D Clinical Program And Updated Preliminary Data From Phase 1/2 TARGET-D 101 Dose Escalation And Dose Expansion Trial

Verastem, Inc.

Verastem, Inc.

VSTM

0.00

Featuring updated preliminary clinical data across tumor types from the Phase 1/2 TARGET-D 101 trial

Company to host investor conference call and webcast on Tuesday, June 23, 2026, at 4:30 pm ET

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.